Clinical trials: Influenza H1N1
Serology Analysis, Novel H1N1 Influenza Vaccination
Antibody Titer Analysis After H1N1 Vaccination in Pediatric Haemato-oncology Patients
The patients of pediatric haemato-oncology have a higher risk for novel H1N1 influenza infection than general population, and they are strongly recommended to receive novel H1N1 vaccination.
- Conditions
- Serology Analysis, Novel H1N1 Influenza Vaccination, Pediatric Haemato-oncology Patients
- Trial name
- NCT01046227
- Testing
- Influenza A (H1N1) 2009 monovalent vaccine, inactivated
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
HIV Infections
Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)
A 1-year multicenter, randomized, single-blinded, phase II trial, stratified on HAART. The purpose of this trial is to evaluate the immunogenicity and safety of a A(H1N1)French National Agency for Research on AIDS and Viral…
- Trial name
- NCT01008813
- Testing
- adjuvanted A(H1N1)v influenza vaccine, non-adjuvanted A(H1N1)v influenza vaccine
- Where
- 6 sites in France
- Volunteers
- 306 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Clinically Suspected H1N1 Infection
Influenza A H1N1: Retrospective Analysis of PCR Confirmed Cases of H1N1 Infections in Styria - Risk Factors, Clinical Features and Outcome.
This retrospective study will analyse all PCR-proven H1N1 cases from the influenza season 2009/2010 treated within the styrian "LKH hospital network".
- Trial name
- NCT01343979
- Where
- Austria
- Volunteers
- 800 people
- Sponsor
- Medical University of Graz
Influenza
Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults
This is a multicenter, escalating dose-ranging study to assess the safety, reactogenicity and immunogenicity of 3 different novel H1N1 influenza vaccine constructs delivered i.m. as a single dose vaccination on day 0.
- Trial name
- VAX128-01 (NCT01172054)
- Testing
- VAX128
- Where
- 2 sites in United States
- Volunteers
- 292 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
Decreased Immunologic Activity [PE], Influenza
Influenza A/H1N1/2009-adjuvanted Vaccine in Renal Disease Patients
In 2009, the pandemic influenza A/H1N1 accounted for worldwide recommendations about vaccination. There is no data concerning the immunogenicity nor the security of the adjuvanted-A/H1N1 vaccine in renal disease patients.
- Conditions
- Decreased Immunologic Activity [PE], Influenza, Rejection
- Trial name
- NCT01298102
- Testing
- Influenza A/H1N1 2009-AS03 adjuvanted (Pandemrix)
- Where
- Belgium
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Erasme University Hospital
Influenza
Swine Flu (Novel Influenza A H1N1) Vaccine Study
In the first half of this year a novel Influenza A H1N1 virus has resulted in an influenza pandemic. The United Kingdom has seen a particularly high incidence of disease.
- Trial name
- NCT00980850
- Testing
- Baxter Novel Influenza A H1N1 Whole Virus Vaccine, GlaxoSmithKline Novel Influenza A H1N1 Split Virion Vaccine
- Where
- 5 sites in United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Influenza
Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine
The purpose of the study is to determine the amount of live virus that can be recovered from the nose of people who are vaccinated with the licensed live vaccine against H1N1, and to describe the immune response to vaccination.
- Trial name
- NCT01023776
- Testing
- A/California/07/09 live monovalent H1N1 vaccine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Influenza
H1N1v Virus Challenge Study in Healthy Subjects
This is a study of a reverse-engineered, Good Manufacturing Practice (GMP) grade, antiviral-sensitive, influenza A/Bethesda/MM2/H1N1 virus (A/California/04/2009/H1N1-like) infection to assess the effect of pre-existing immunity…
- Trial name
- NCT04044352
- Testing
- Influenza A/Bethesda/MM2/H1N1 Challenge
- Where
- 4 sites in United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older
The purpose of this study is to comply with the post marketing condition to the exceptional approval of Arepanrix™ in Japan and to assess the immunogenicity and safety of GSK Biologicals' H1N1 influenza vaccine healthy Japanese…
- Trial name
- NCT01114620
- Testing
- Arepanrix™
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Intramuscular CodaVax-H1N1 in Healthy Adults
This study is a Phase 1, 2-part, randomised, double-blind, controlled, clinical trial to evaluate the safety and immune response of CodaVax-H1N1 in healthy adults aged 18 to 49 years.
- Trial name
- NCT05223179
- Testing
- CODA-VAX H1N1, Flucelvax Quad, Saline
- Where
- Australia
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Codagenix, Inc
Novel Influenza A (H1N1), A New Flu Virus of Swine Origin
Observational Study of Safety of Flu Cell Culture Derived Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Vaccine
This is an observational study of safety and occurrence of influenza-like illness following administration of flu cell culture derived adjuvanted swine origin A (H1N1) pandemic subunit vaccine in subjects 6 months of age and…
- Trial name
- NCT01037855
- Testing
- Non-intervention observational study
- Where
- 10 sites in Chile, Colombia and 2 more
- Volunteers
- 4,028 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Swine-origin A/H1N1 Influenza
A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in adults and the elderly. Primary Objectives: To describe the immunogenicity of the candidate vaccines after a single injection.
- Trial name
- NCT00952276
- Testing
- Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant, Monovalent Subvirion A/H1N1 influenza vaccine, Normal saline solution
- Where
- 15 sites in United States
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza
H1N1 Vaccine at Two Dose Levels in HIV Positive Adults
The purpose of this study is to see how the body reacts to different strengths of the H1N1 flu shot in persons infected with human immunodeficiency virus (HIV).
- Trial name
- NCT00992433
- Testing
- Inactivated Influenza H1N1 vaccine
- Where
- 6 sites in United States
- Volunteers
- 192 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
H1N1 Influenza Virus, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection
This is a phase III, randomized, controlled, open label study with two vaccine regimens. The study will assess the relative safety and immunogenicity of vaccine regimens comparing adjuvanted versus non-adjuvanted formulations of…
- Trial name
- NCT01032408
- Testing
- Focetria®, Begrivac®
- Where
- 2 sites in Brazil
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Chiltern Pesquisa Clinica Ltda
Influenza, Human
Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults
The purpose of this phase I/II trial is to evaluate safety and tolerability of a single dose of GHB16L2 administered by liquid nasal spray for vaccination against seasonal influenza virus infection.
- Trial name
- NCT01369862
- Testing
- GHB16L2
- Where
- Austria
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- AVIR Green Hills Biotechnology AG
HIV
Vaccination Response in ImmunoCompromised Host. Immune Response After Vaccination Against Pandemic A/H1N1 Influenza
As recommended by the Dutch Health Council, certain risk groups and health care workers in The Netherlands were vaccinated to prevent morbidity due to pandemic influenza A/H1N1.
- Trial name
- RICH-3 (NCT01066169)
- Testing
- Foceteria® (Novartis)
- Where
- Netherlands
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Influenza
Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old
This study is designed to characterize the safety and immunogenicity of pandemic influenza (H1N1) candidate vaccines GSK2340274A and GSK234072A in children 3 to less than 10 years old.
- Trial name
- NCT01161160
- Testing
- GSK Biologicals' GSK2340274A (two different formulations), GSK Biologicals' - GSK2340272A
- Where
- 2 sites in Philippines, Thailand
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model
FLU-v is a broad spectrum influenza vaccine that targets regions conserved among multiple influenza strains. FLU-v adjuvanted with Montanide ISA-51 was shown to be safe in previous trials.
- Trial name
- NCT03180801
- Testing
- adjuvanted FLU-v, Influenza challenge
- Where
- United Kingdom
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- PepTcell Limited
HIV Infections, H1N1 Influenza
Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV
The purpose of this study is to assess the safety and effectiveness (immune response) to a licensed H1N12009 influenza vaccine in HIV-infected adults. The study will enroll 150 adults (ages 20-59 years).
- Trial name
- NCT01002040
- Testing
- Arepanrix
- Where
- 4 sites in Canada
- Volunteers
- 150 people
- Sponsor
- University of British Columbia
Covid19, Influenza A
Vitamine D3 Supplementation in Patients With Serum Values +/- 20ng/ml
Scarce information exists in relation to the effect of supplementation of Vitamin D3 in SARS-COV-2 infection, H1N1, and A, B Influenza when 25-hydroxyvitamin levels are between 20-100ng/ml.
- Conditions
- Covid19, Influenza A, Influenza B, H1N1 Influenza
- Trial name
- NCT04810949
- Testing
- Vitamine D3 supplementation, Diet and sun exposure
- Where
- Mexico
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Hospital Clinica Nova